

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035522 A1

(51) International Patent Classification⁷: **C07D 401/04**,
405/04, 211/52, 417/04, A61K 31/451, 31/4523, A61P
25/00

Pfizer Japan Inc., 2 Aza 5-gochi, Taketoyo-cho, Chita-gun,
Aichi-ken 470-2393 (JP).

(21) International Application Number:
PCT/IB2004/003127

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(22) International Filing Date:
27 September 2004 (27.09.2004)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/509,643 8 October 2003 (08.10.2003) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for JP only*): **PFIZER JAPAN, INC.** [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).

(71) Applicant (*for all designated States except JP, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **ANDO, Kazuo**
[JP/JP]; Pfizer Global Research and Development,
Nagoya, Pfizer Japan Inc., 2 Aza 5-gochi, Taketoyo-cho,
Chita-gun, Aichi-ken 470-2393 (JP). **HIROTA, Masako**
[JP/JP]; Pfizer Global Research and Development, Nagoya,

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 1-(2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL)-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS



(I)

(57) Abstract: This invention provides a compound of the formula (I), wherein R¹ and R² independently represents a hydrogen atom or the like; R³ represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups having from 6 to 10 ring carbon atoms and said heteroaryl groups having from 5 to 10 atoms are unsubstituted or are substituted by at least one substituent selected from the group consisting of substituents a; said substituents a are selected from the group consisting of halogen atoms or the like; or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of

NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.